IceCure Medical Ltd (ICCM)
| Market Cap | 55.79M |
| Revenue (ttm) | 3.23M |
| Net Income (ttm) | -14.65M |
| Shares Out | 45.73M |
| EPS (ttm) | -0.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 99,866 |
| Open | 1.260 |
| Previous Close | 1.210 |
| Day's Range | 1.180 - 1.260 |
| 52-Week Range | 0.520 - 1.570 |
| Beta | 2.97 |
| Analysts | Strong Buy |
| Price Target | 2.95 (+141.8%) |
| Earnings Date | Apr 3, 2024 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. The company was incorporated in 2006 and is headquartered in Caesarea, Israel. [Read more]
Financial Performance
In 2023, ICCM's revenue was $3.23 million, an increase of 4.67% compared to the previous year's $3.09 million. Losses were -$14.65 million, -13.70% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ICCM stock is "Strong Buy." The 12-month stock price forecast is $2.95, which is an increase of 141.80% from the latest price.
News
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer
Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of th...
IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance
Conference call to be held today at 10:00 am Eastern Time; Focus on U.S. market for ProSense® in breast cancer indication CAESAREA, Israel , April 3, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:...
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems CAESAREA, Israel , April 2, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure...
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Overview of U.S. Commercial Strategy will be Discussed on Conference Call CAESAREA, Israel , March 27, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer ...
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Expects to submit full dataset to the FDA in April for marketing authorization of ProSense® for minimally invasive treatment of early-stage breast cancer Study represents largest cryoablation study of...
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes
Innovating as a global leader in cryoablation technologies, with 42 patents issued and allowed Cryogenic flow control enhances the efficacy and precision of cryoablation procedures CAESAREA, Israel , ...
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
CAESAREA, Israel , March 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
MRI reveals disappearance of hemorrhagic signal and development of necrotic changes Pain reduced from a median of 7 on a scale of 0 - 10 to a median of 1, with some patients reporting 0 CAESAREA, Is...
Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop
Session conducted by Dr. Rupa Renganathan, who performed India's first breast cancer cryoablation procedure with ProSense®; Expert interview with Dr. Hania Bednarski, who has performed cryoablation br...
Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer
Independent study in women deemed inoperable for breast cancer reports median tumor reduction of 100% at 6 and 12 months following cryoablation CAESAREA, Israel , Feb. 26, 2024 /PRNewswire/ -- IceCure...
IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
CAESAREA, Israel , Feb. 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that ...
U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer
IceCure to submit full 5-year dataset from entire ICE3 study population to the FDA this spring, ahead of previous expectation CAESAREA, Israel , Jan. 30, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NAS...
IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
IceCure exhibits and provides hands-on demonstrations at SIO 2024 Annual Meeting in California, receiving enthusiastic response from interventional oncologists ICE3 trial data were central to the Brea...
IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation
ProSense® users speaking at the conference about cryoablation included ISVIR President Dr. Suyash Kulkarni, as well as Dr. Shuvro Roy-Choudhury CAESAREA, Israel , Jan. 16, 2024 /PRNewswire/ -- IceCure...
IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
CAESAREA, Israel, Jan. 12, 2024 (GLOBE NEWSWIRE) -- IceCure Medical Ltd. (Nasdaq: ICCM) (“IceCure” or the “Company”), developer of the ProSense® System, a minimally-invasive cryoablation technology th...
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
U.S. sales continue to increase with 25% jump in ProSense® system and disposable probe sales in 2023 over prior year ICE3 study is set for completion and final data read out CAESAREA, Israel , Jan. 10...
New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
Independent mouse study conducted at Case Western Reserve University School of Medicine, published in OncoImmunology, builds on body of evidence demonstrating cryoablation can activate the body's natu...
Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"
Independent study published in Annals of Surgical Oncology concludes cryoablation is an oncologically safe and feasible minimally invasive procedure option in lieu of surgery for patients with early...
IceCure's ProSense® Deepens Regulatory Approval in India
ProSense® is already marketed and sold in India based on previous regulatory requirements and now has been re-classified due to new regulations Breast cancer cryoablation is already performed in India...
IceCure System Successfully Treated Kidney Cancer Tumor with 92% Disease-Free Survival Rate and 100% Secondary Local Control Rate
Independent study concluded: - IceCure system offers significant advantage in ability to re-treat tumors that are initially resistant, achieving a subsequent local control rate of 100% - 92.4% of pati...
IceCure Medical Reports Financial Results as of and for the Nine Months Ended September 30, 2023, and Provides Update on Recent Operational Highlights
ProSense® system and disposables sales continue upward trend compared to the equivalent prior year period Expanded regulatory footprint, growing body of evidenced-based data, and distribution agreemen...
IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
Objective is to reopen file to address comments and find appropriate comparator group that is more representative of the patient population the Company is seeking to treat with its ProSense® system Co...
IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023
CAESAREA, Israel , Nov. 8, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablatio...
Substantial Evidence-Based Data Currently Being Generated by 19 Ongoing Studies Using IceCure Medical's ProSense® Cryoablation System
Independent, non-sponsored studies by doctors using ProSense® to treat cancers of the breast, lung, kidney, and musculoskeletal system, as well as endometriosis and fibroadenomas Growing body of scien...
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
CAESAREA, Israel , Nov. 3, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), a developer of the ProSense® System, a minimally-invasive cryoablation technology that...